Roche CEO cites European pricing pressure; Baxter spinoff on track for midyear;

@FiercePharma: Dog data at AACR cancer confab may point to personalized treatments. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Chinese API maker Yunnan Hande Bio-Tech gets a second FDA warning letter. Report | Follow @EricPFierce

@CarlyHFierce: Pfizer's Lyrica team matches the spokesman to the message. FiercePharmaMarketing article | Follow @CarlyHFierce

> Roche ($RHHBY) CEO Severin Schwan said the company's oncology franchise will continue to drive growth, despite ongoing pricing pressure in Europe. Report

> Baxter International ($BAX) first-quarter earnings fell by 23%, partly because of negative currency effects; its biopharma spinoff remains on track for midyear, executives said. Report (sub. req.)

> Amgen ($AMGN) sales took an 11% leap in the first quarter, as its old standby Enbrel and newer Prolia/Xgeva franchise helped offset generic competition and currency effects. Release

> Two psychiatrists with financial ties to AstraZeneca ($AZN) quit a Texas state hospital after they were told they faced disciplinary action for taking speaking and consulting fees from the company. Report (sub. req.)

> The nursing home pharmacy services company Omnicare is working with financial advisers on a possible sale, Bloomberg says. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: WuXi and DNAnexus join up for cloud-based genomic services. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: FDA issues new guidelines on acceptance of data from overseas clinical trials. Story | Follow @VarunSaxena2

@EmilyWFierce: FBI admits to decades of flawed hair analysis. Washington Post story | Follow @EmilyWFierce

> Diabetes device sales bounce back at Abbott with FreeStyle Libre. More

> St. Jude aims for Axium approval before year-end, with robust neuromodulation growth in 2016. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Salk heavyweight Evans raising $33M for an intriguing stealth biotech. Article | Follow @FierceBiotech

@JohnCFierce: The next-next gen thing: Merck and Gilead square off in battle of the next-next-gen hep C combos. Report | Follow @JohnCFierce

> Take two: Is Clovis Oncology a buyout target? Item

> Juno and AstraZeneca pair two hot immunotherapies in new cancer study. Article

> Novartis' 'megablockbuster' heart drug LCZ696 wins another rave preview. Report

CRO News

> BioClinica recruits a new eClinical president amid rapid expansion. Item

> WuXi deepens its genomic ties with latest partnership. More

> India's Biocon eyes an IPO for its in-house CRO. Story

> Sartorius snags U.K. CRO BioOutsource with an eye on biosimilars. More

> PPD reaches into China with a new central lab. Article

Vaccines News

> Mymetics-led consortium scores €8.4M to develop thermostable vaccines. More

> PaxVax expands commercial network for typhoid vaccine. Report

> CSL CFO to lead flu vaccine business after 2016 launch. Item

> Sinovac to trial jabs with potential to disrupt Pfizer, GSK in China. Story

> Potency worries prompt GSK flu vaccine recall. Article

Pharma Manufacturing News

> Study finds essential antibiotics are often in short supply in U.S. Item

> Indicted compounder filled prescriptions with fake patient names Silver Surfer, Coco Puff. Report

> Counterfeit Botox again found in the U.S. More

> Bayer to close vet med plant, lay off 130. Story

> Labeling foul-up involving acetaminophen leads RB to recall 135 lots of Mucinex. Article

Pharma Asia News

> Founder Dilip Shanghvi did not buy Daiichi stake, Sun Pharmaceutical says. Item

> China proposes patent law changes to toughen IP protection. More

> Biocon plans India listing for Syngene in R&D funding move. Report

> South Korea's SillaJen eyes Phase III for immunotherapy oncology candidate. Story

> Japan researchers look to upset apple cart of pharma manufacturing costs. Article

And Finally... The language we speak--and words we choose--appear to shape our thoughts and viewpoints. Report (sub. req.)

Suggested Articles

After a slow start, Teva's Ajovy launch is improving following the FDA approval for an autoinjector.

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.